<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02815176</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02-109</org_study_id>
    <nct_id>NCT02815176</nct_id>
  </id_info>
  <brief_title>Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers</brief_title>
  <official_title>Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombotic biomarkers and angiographic characteristics were compared among the de novo
      patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV)
      and the control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Fibrinogen in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum Fibrinogen (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Factor VIII activity in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum Factor VIII activity (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Plasminogen activity in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum Plasminogen activity (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum D-dimer in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum D-dimer (μg/mL(FEU))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Fibrin degradation product in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum Fibrin degradation product (μg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PAI-1 antigen in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum PAI-1 (plasminogen activator inhibitor-1) antigen (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum PAI-1 SNP genotyping in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Serum PAI-1 SNP(single nucleotide polymorphism) genotyping</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics of fluorescein angiography in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Numbers of leaking points of fluorescein dye in fluorescein angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of indocyanine green angiography in active PCV and CSC patients</measure>
    <time_frame>Less than 1 week after initial diagnosis</time_frame>
    <description>Numbers of hyperfluorescent spots in indocyanine green angiography</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Central serous chorioretinopathy</arm_group_label>
    <description>De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polypoidal choroidal vasculopathy</arm_group_label>
    <description>De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiretinal membrane</arm_group_label>
    <description>Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Sampling the blood including DNA to investigate the thrombotic profile</description>
    <arm_group_label>Central serous chorioretinopathy</arm_group_label>
    <arm_group_label>Polypoidal choroidal vasculopathy</arm_group_label>
    <arm_group_label>Epiretinal membrane</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples including DNA will be retained to perform the genotyping analysis of PAI-1 SNP.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        De novo patients with active CSC and PCV.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CSC

               -  neurosensory detachment in optical coherence tomography (OCT)

               -  focal leakage in fluorescein angiography (FAG) and/or late choroidal
                  hyperpermeability in indocyanine green angiography (ICGA)

          -  PCV

               -  subretinal and/or sub-retinal pigment epithelial fluid in OCT

               -  branching vascular network and/or polyps in ICGA

          -  Control

               -  epiretinal membrane (ERM)

               -  without underlying systemic, ophthalmic disease other than ERM

        Exclusion Criteria:

          -  Previous history of using steroid (oral, topical)

          -  Previous history of CSC/PCV

          -  Previous history or evidence of intraocular inflammation including uveitis

          -  Co-existing retinal or choroidal diseases

          -  History of allergic reaction to fluorescein or indocyanine green dye

          -  Underlying systemic conditions that could affect the thrombotic profiles (e.g.
             diabetes, hypertension, metabolic syndrome, coronary artery disease, cerebrovascular
             diseases, stroke, chronic renal failure, current smoker, pregnancy, sleep disorder)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunho Bae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of ophthalmology, Samsung medical center, Seoul, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Se Woong Kang, MD</last_name>
    <phone>+82-2-3410-3548</phone>
    <email>swkang@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Woong Kang, MD</last_name>
      <phone>+82-2-3410-3548</phone>
      <email>swkang@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kunho Bae, MD</last_name>
      <phone>+82-10-9933-5224</phone>
      <email>luben81@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Se Woong Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kunho Bae, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Min Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyuyeon Cho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>June 28, 2016</last_update_submitted>
  <last_update_submitted_qc>June 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasminogen activator inhibitor-1</keyword>
  <keyword>Wide angle fluorescein angiography</keyword>
  <keyword>Choroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Plasminogen Inactivators</mesh_term>
    <mesh_term>Plasminogen Activator Inhibitor 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

